1. Home
  2. CTNM vs EUDA Comparison

CTNM vs EUDA Comparison

Compare CTNM & EUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • EUDA
  • Stock Information
  • Founded
  • CTNM 2009
  • EUDA 2021
  • Country
  • CTNM United States
  • EUDA Singapore
  • Employees
  • CTNM N/A
  • EUDA N/A
  • Industry
  • CTNM
  • EUDA Blank Checks
  • Sector
  • CTNM
  • EUDA Finance
  • Exchange
  • CTNM Nasdaq
  • EUDA Nasdaq
  • Market Cap
  • CTNM 142.3M
  • EUDA 146.0M
  • IPO Year
  • CTNM 2024
  • EUDA N/A
  • Fundamental
  • Price
  • CTNM $5.77
  • EUDA $3.20
  • Analyst Decision
  • CTNM Strong Buy
  • EUDA
  • Analyst Count
  • CTNM 4
  • EUDA 0
  • Target Price
  • CTNM $22.50
  • EUDA N/A
  • AVG Volume (30 Days)
  • CTNM 366.4K
  • EUDA 93.2K
  • Earning Date
  • CTNM 08-12-2025
  • EUDA 01-01-0001
  • Dividend Yield
  • CTNM N/A
  • EUDA N/A
  • EPS Growth
  • CTNM N/A
  • EUDA N/A
  • EPS
  • CTNM N/A
  • EUDA N/A
  • Revenue
  • CTNM N/A
  • EUDA $4,011,005.00
  • Revenue This Year
  • CTNM N/A
  • EUDA $212.19
  • Revenue Next Year
  • CTNM N/A
  • EUDA $254.35
  • P/E Ratio
  • CTNM N/A
  • EUDA N/A
  • Revenue Growth
  • CTNM N/A
  • EUDA 8.22
  • 52 Week Low
  • CTNM $3.35
  • EUDA $2.92
  • 52 Week High
  • CTNM $21.58
  • EUDA $6.30
  • Technical
  • Relative Strength Index (RSI)
  • CTNM N/A
  • EUDA 44.68
  • Support Level
  • CTNM N/A
  • EUDA $2.95
  • Resistance Level
  • CTNM N/A
  • EUDA $3.38
  • Average True Range (ATR)
  • CTNM 0.00
  • EUDA 0.13
  • MACD
  • CTNM 0.00
  • EUDA -0.00
  • Stochastic Oscillator
  • CTNM 0.00
  • EUDA 56.82

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About EUDA EUDA Health Holdings Limited

EUDA Health Holdings Ltd is a non-invasive healthcare company across Southeast Asia and China. The Company has two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include common area property management services that contain cleaning, landscaping, public facilities maintenance and other traditional services and also include security property management services provided to all tenants and property owners.

Share on Social Networks: